Advertisement

The Association Between Drug Burden Index (DBI) and Health-Related Outcomes: A Longitudinal Study of the ‘Oldest Old’ (LiLACS NZ)

  • Karen CardwellEmail author
  • Ngaire Kerse
  • Cristín Ryan
  • Ruth Teh
  • Simon A. Moyes
  • Oliver Menzies
  • Anna Rolleston
  • Joanna Broad
  • Carmel M. Hughes
Original Research Article

Abstract

Background

The prescribing of medications with anticholinergic and/or sedative properties is considered potentially inappropriate in older people (due to their side-effect profile), and the Drug Burden Index (DBI) is an evidence-based tool which measures exposure to these medications. Life and Living in Advanced Age: a Cohort Study in New Zealand (LiLACS NZ) is an ongoing longitudinal study investigating the determinants of healthy ageing. Using data from LiLACS NZ, this study aimed to determine whether a higher DBI was associated with poorer outcomes (hospitalisation, falls, mortality and cognitive function and functional status) over 36 months follow-up.

Methods

LiLACS NZ consists of two cohorts: Māori (the indigenous population of New Zealand) aged ≥ 80 years and non-Māori aged 85 years at the time of enrolment. Data relating to regularly prescribed medications at baseline, 12 months and 24 months were used in this study. Medications with anticholinergic and/or sedative properties (i.e. medications with a DBI > 0) were identified using the Monthly Index of Medical Specialities (MIMS) medication formulary, New Zealand. DBI was calculated for everyone enrolled at each time point. The association between DBI at baseline and outcomes was evaluated throughout a series of 12-month follow-ups using negative binomial (hospitalisations and falls), Cox (mortality) and linear (cognitive function and functional status) regression analyses (significance p < 0.05). Regression models were adjusted for age, gender, general practitioner (GP) visits, socioeconomic deprivation, number of medicines prescribed and one of the following: prior hospitalisation, history of falls, baseline cognitive function [Modified Mini-Mental State Examination (3MS)] or baseline functional status [Nottingham Extended Activities of Daily Living (NEADL)].

Results

Full demographic data were obtained for 671, 510 and 403 individuals at baseline, 12 months and 24 months, respectively. Overall, 31%, 30% and 34% of individuals were prescribed a medication with a DBI > 0 at baseline, 12 months and 24 months, respectively. At baseline and 12 months, non-Māori had a greater mean DBI (0.28 ± 0.5 and 0.27 ± 0.5, respectively) compared to Māori (0.16 ± 0.3 and 0.18 ± 0.5, respectively). At baseline, the most commonly prescribed medicines with a DBI > 0 were zopiclone, doxazosin, amitriptyline and codeine. In Māori, a higher DBI was significantly associated with a greater risk of mortality: at 36 months follow-up, adjusted hazard ratio [95% confidence interval (CI)] 1.89 (1.11–3.20), p = 0.02. In non-Māori, a higher DBI was significantly associated with a greater risk of mortality [at 12 months follow-up, adjusted hazard ratio (95% CIs) 2.26 (1.09–4.70), p = 0.03] and impaired cognitive function [at 24 months follow-up, adjusted mean difference in 3MS score (95% CIs) 0.89 (− 3.89 to − 0.41), p = 0.02).

Conclusions

Using data from LiLACS NZ, a higher DBI was significantly associated with a greater risk of mortality (in Māori and non-Māori) and impaired cognitive function (in non-Māori). This highlights the importance of employing strategies to manage the prescribing of medications with a DBI > 0 in older adults.

Notes

Acknowledgements

We thank all the participants and their whanau/families for their time and contribution to the principal study. The Rōpū Kaitiaki (Hone Kameta, Florence Kameta, Betty McPherson, Te Kaanga Skipper, Paea Smith and Laiana Reynolds) oversaw the project from feasibility and throughout recruitment. Elizabeth Robinson guided the biostatistical planning, and Rudi Westendorp gave advice at the planning stages.

Compliance with Ethical Standards

Funding

Funding was provided by Department for Employment and Learning, Northern Ireland.

Conflict of interest

KC, NK, CR, RT, SM, OM, AR, JB and CH declare that they have no conflict of interest. This current analysis was supported by the Department for Employment and Learning (DEL), Northern Ireland, through a postgraduate studentship to KC. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Supplementary material

40266_2019_735_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    Bostock CV, Soiza RL, Mangoni AA. Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Ther Adv Drug Saf. 2013;4:235–45.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, Hartikainen S. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging. 2013;30:321–30.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between Drug Burden Index and falls in older people in residential aged care. J Am Geriatr Soc. 2011;59:875–80.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099–103.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Lowry E, Woodman RJ, Soiza RL, Mangoni AA. Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc. 2011;12:565–72.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Kumpula EK, Bell JS, Soini H, Pitkälä KH. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol. 2011;51:256–63.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179:1084–93.PubMedCentralCrossRefGoogle Scholar
  8. 8.
    Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14.CrossRefGoogle Scholar
  10. 10.
    Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Hilmer SN, Mager DE, Simonsick EM, Coa Y, Ling SM, Windham BG. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781–7.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kouladjian L, Gnjidic D, Chen TF, Mangoni AA, Hilmer SN. Drug Burden Index in older adults: theoretical and practical issues. Clin Inter Ageing. 2014;9:1503–15.CrossRefGoogle Scholar
  13. 13.
    Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the “oldest old”: a systematic review of the literature. Drugs Aging. 2015;32:835–48.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Guralnik JM, Kritchevsky SB. Translating research to promote healthy ageing: the complementary role of longitudinal studies and clinical trials. J Am Geriatr Soc. 2010;58:S337–42.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Hayman KJ, Kerse N, Dyall L, Kepa M, Teh R, Wham C, et al. Life and Living in advanced age: a cohort study in New Zealand-Te Puāwaitanga o Nga Tapuwae Kia Ora Tonu, LiLACS NZ: study protocol. BMC Geriatr. 2012;12(33):1.Google Scholar
  16. 16.
    Stats NZ Tatauranga Aotearoa. Māori population estimates: At 30 June 2018 [Internet]. Wellington: Stats NZ Tatauranga Aotearoa; 2018. https://www.stats.govt.nz/information-releases/maori-population-estimates-at-30-june-2018. Accessed 15 Nov 2019.
  17. 17.
    Ellison-Loschmann L, Pearce N. Improving access to health care among New Zealand’s Maori population. Am J Public Health. 2006;96:612–7.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Jones R, Crowshoe L, Reid P, Calam B, Curtis E, Green M, et al. Educating for indigenous health equity. Acad Med. 2019;94:512–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Dyall L, Kepa M, Hayman K, Teh R, Moyes S, Broad J, et al. Engagement and recruitment of Māori and non-Māori people of advanced age to LiLACS NZ. Aust N Z J Public Health. 2013;37:124–31.PubMedCrossRefGoogle Scholar
  20. 20.
    The Best Practice Advocacy Centre New Zealand. History of rongoā Māori [Internet]. Dunedin: The Best Practice Advocacy Centre New Zealand. https://bpac.org.nz/bpj/2008/may/docs/bpj13_rongoa_pages_32-36.pdf. Accessed 15 Nov 2019.
  21. 21.
    Teh R, Doughty R, Connolly M, Broad J, Pillai A, Wilkinson T, et al. Agreement between self-reports and medical records of cardiovascular disease in octogenarians. J Clin Epidemiol. 2013;66:1135–43.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Salmond C, Crampton P. NZDEP96-what does it measure? Soc Policy J N Z. 2001;17:82–100.Google Scholar
  23. 23.
    MIMS New Zealand Ltd. MIMS New Zealand [Internet]. Auckland: MIMS New Zealand Ltd. http://www.mims.co.nz/. Accessed 15 Nov 2019.
  24. 24.
    World Health Organization Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology; 2017. ATC/DDD Index 2017; 2016 Dec 19. http://www.whocc.no/atc_ddd_index/. Accessed 15 Nov 2019.
  25. 25.
    Teng EL, Ph D, Chui HC. The modified mini-mental state (3MS) examination. J Clin Psychiatry. 1987;48:314–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Essink-Bot M-L, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. Med Care. 1997;35:522–37.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Lönnroos E, Gnjidic D, Hilmer SN, Bell JS, Kautiainen H, Sulkava R, et al. Drug Burden Index and hospitalization among community-dwelling older people. Drugs Aging. 2012;29:395–404.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Gnjidic D, Bell JS, Hilmer SN, Lönnroos E, Sulkava R, Hartikainen S. Drug Burden Index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44:458–67.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol. 2009;68:97–105.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. Drug Burden Index and Beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol. 2012;52:258–65.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Harris R, Cormack D, Tobias M, Yeh LC, Talamaivao N, Minster J, et al. The pervasive effects of racism: experiences of racial discrimination in New Zealand over time and associations with multiple health domains. Soc Sci Med. 2012;74:408–15.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Stafford M, Marmot M. Neighbourhood deprivation and health: does it affect us all equally? Int J Epidemiol. 2003;32:357–66.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Nishtala PS, Narayan SW, Wang T, Hilmer SN. Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Saf. 2014;23:753–8.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJ. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013;43:912–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Wilson NM, Hilmer SN, March LM, Chen JS, Gnjidic D, Mason RS, et al. Associations between Drug Burden Index and mortality in older people in residential aged care facilities. Drugs Aging. 2012;29:157–65.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing. 2010;39:503–7.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Pitama S, Huria T, Lacey C. Improving Māori health through clinical assessment: Waikare o te Waka o Meihana. N Z Med J. 2014;127:1393.Google Scholar
  38. 38.
    Ministry of Health. The Health of Māori Adults and Children [Internet]. Wellington: Ministry of Health; 2013. http://www.health.govt.nz/system/files/documents/publications/health-maori-adults-children-summary.pdf. Accessed 15 Nov 2019.
  39. 39.
    Gnjidic D, Hilmer SN, Hartikainen S, Tolppanen A-M, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer’s disease: a national population cohort study. PLoS One. 2014;9:e83224.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Kashyap M, Belleville S, Mulsant BH, Hilmer SN, Paquette A, Tu LM, et al. Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc. 2014;62:336–41.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Lowry E, Woodman RJ, Soiza RL, Hilmer SN, Mangoni AA. Drug Burden Index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol. 2012;52:1584–91.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Keyzer JF, Melnikow J, Kuppermann M, Birch S, Kuenneth C, Nuovo J, et al. Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview. Ethn Dis. 2005;15:395–406.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Levy HB, Marcus EL, Christen C. Beyond the Beers criteria: a comparative overview of explicit criteria. Ann Pharmacother. 2010;44:1968–75.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Wilkinson S, Mulder RT. Antipsychotic prescribing in New Zealand between 2008 and 2015. N Z Med J. 2018;131:1480.Google Scholar
  45. 45.
    Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry. 2013;21:785–93.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dement Geriatr Cogn Dis Extra. 2012;2:361–71.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB, et al. Drug burden index score and functional decline in older people. Am J Med. 2009;122:1142–9.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Naja M, Zmudka J, Hannat S, Liabeuf S, Serot JM, Jouanny P. In geriatric patients, delirium symptoms are related to the anticholinergic burden. Geriatr Gerontol Int. 2016;16:424–31.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013;68:271–8.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Young AF, Powers JR, Bell SL. Attrition in longitudinal studies: who do you lose? Aust N Z J Public Health. 2006;30:353–61.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Frank KA. Impact of a confounding variable on a regression coefficient. Sociol Method Res. 2000;29:147–94.CrossRefGoogle Scholar
  52. 52.
    Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185–91.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Northern Ireland Centre for Pharmacy Learning and Development, School of PharmacyQueen’s University BelfastBelfastNorthern Ireland, UK
  2. 2.Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  3. 3.School of Pharmacy and Pharmaceutical Science, Trinity College DublinThe University of DublinDublin 2Ireland
  4. 4.Older People’s Health, Auckland District Health BoardAucklandNew Zealand
  5. 5.The Centre for HealthTaurangaNew Zealand
  6. 6.Department of Geriatric Medicine, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  7. 7.School of PharmacyQueen’s University BelfastBelfastNorthern Ireland, UK

Personalised recommendations